Molecular biology applications company New England Biolabs (NEB) announced on Tuesday that it has awarded USD100,000 to the Vaccine and Immunotherapy Center (VIC) at Mass General Hospital (MGH), to support the search for a vaccine against the novel coronavirus, SARS-CoV-2.
Established in 2008, the VIC at MGH will accelerate the translation of laboratory discoveries into new, safe, broadly applicable cost-effective vaccines and therapies to prevent and cure various forms of infectious diseases, including the novel coronavirus, SARS-CoV-2, which causes the disease COVID-19.
NEB provides reagents and technical support to researchers around the world who are working to develop new diagnostic tools and vaccines for the COVID-19 virus.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial